Secukinumab not checked

Novartis Pharmaceuticals · AIN457 low dose · AIN457 high dose

FollowEvery change as it happens, and a Monday email
Stage
in the US · approved in the EU
Next date
Phase 4 trial completes
Trials
9 active
61 in total · 16 in the EU
Targets
 

What this is

How it works
An antibody: a lab-made immune protein built to latch onto one target in the body.-mab: monoclonal antibodies WHO name stem
How it’s given
“Treatment Period 2: Double-blind secukinumab 150 mg PFS s.c. every 4 weeks from Week 56 to Week 116. Escape re-treatment (during Treatment Period 2): Open-label secukinumab 150 mg PFS s.c.”In the company’s words, NCT05622708 on ClinicalTrials.gov
Tested for
Non-radiographic Axial Spondyloarthritis, Hidradenitis Suppurativa (HS), Autoimmunity, Inflammation, Polymyalgia Rheumatica, Juvenile Psoriatic Arthritis
Main trialPhase 4
“This study will establish whether prolonged chronic dosing with secukinumab is needed in participants with Non-radiographic axial spondyloarthritis, (nr-axSpA) who have achieved remission. Remission is defined as Ankylosing Spondylitis Disease Activity Score - C-reactive protein (ASDAS-CRP) Inactive Disease (ID) response (ASDAS-CRP \< 1.3). Maintenance of remission on continued secukinumab treatment will be evaluated compared to placebo using a randomized withdrawal design. The primary outcome measure for this study is the proportion of participants remaining flare-free at Week 120.”In the company’s words, NCT05622708 on ClinicalTrials.gov
Other names
AIN457 low dose · AIN457 high dose · AIN457 · AIN457A · AIN457 300 mg · Cosentyx

Other drugs for Non-radiographic Axial Spondyloarthritis

All 3 drugs for Non-radiographic Axial Spondyloarthritis

Copies tested against it2

Other companies’ versions, mostly cheaper copies for when the patent ends

Coming up5

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials61

TrialPhaseCompletesWhat it tests
Phase 4Active, not recruiting 8 Feb 2028 A Study of Secukinumab to Evaluate Maintenance of Response in Participants With Non-radiographic Axial Spondyloarthritis Who Achieved Remission
Phase 4Recruiting 25 Sep 2029 Study of Efficacy and Safety of Secukinumab in Chinese Adult Patients With Moderate to Severe Hidradenitis Suppurativa
Phase 4Recruiting 29 Jan 2030 Secukinumab Open Label Roll-over Extension Protocol
Phase 3Active, not recruiting 8 May 2028 Open-label, Long-term Safety Study of Secukinumab in Polymyalgia Rheumatica (PMR)
Phase 1Recruiting 31 Oct 2029 Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability up to 6 Years of Intravenous (i.v.) Secukinumab in Pediatric Participants With Juvenile Psoriatic Arthritis (JPsA).
Phase 4Completed 26 Apr 2017 Study to Evaluate the Effect of Secukinumab Compared to Placebo on Aortic Vascular Inflammation in Subjects With Moderate to Severe Plaque Psoriasis
Phase 4Completed 25 Apr 2018 Study to Explore the Effect of Secukinumab, Compared to Placebo, on Fat Tissue and Skin in Plaque Psoriasis Patients
Phase 4Completed 5 Dec 2018 Study to Evaluate the Safety and Efficacy of Secukinumab 300 mg and 150 mg in Adult Patients With Active Psoriatic Arthritis (PsA) After 16 Weeks of Treatment Compared to Placebo
Phase 4Completed 24 Sep 2019 Study to Examine the Clinical Efficacy and the Nonsteroidal Anti-inflammatory Drug (NSAID)-Sparing Effect of Secukinumab Over 16 Weeks in Patients With Ankylosing Spondylitis
Phase 4Completed 11 Mar 2021 Study Estimating the Clinical Difference Between 300 mg and 150 mg of Secukinumab Following Dose Escalation to 300 mg in Patients With Ankylosing Spondylitis
Phase 4Withdrawn 24 Mar 2021 An Efficacy Study of Secukinumab in Plaque Psoriasis Patients With Subclinical Psoriatic Arthritis as Measured by Musculoskeletal Ultrasound
Phase 4Completed 30 Nov 2021 Comparison of Secukinumab 300 mg Combined With a Lifestyle Intervention to Secukinumab Alone for the Treatment of Moderate to Severe Psoriasis Patients With Concomitant Metabolic Syndrome
Phase 4Completed 30 Nov 2021 Study of the Efficacy of Early Intervention With Secukinumab 300 mg s.c. Compared to Narrow-band UVB in Patients With New-onset Moderate to Severe Plaque Psoriasis
Phase 3Completed Apr 2013 Efficacy and Safety of Subcutaneous Secukinumab for Moderate to Severe Chronic Plaque-type Psoriasis for up to 1 Year
Phase 3Completed Jul 2013 Safety and Efficacy of Secukinumab Compared to Etanercept in Subjects With Moderate to Severe, Chronic Plaque-Type Psoriasis
Phase 3Completed 7 Dec 2015 Efficacy and Safety of Subcutaneous Secukinumab in Adults With Moderate to Severe Scalp Psoriasis
Phase 3Completed 13 Dec 2018 Pediatric Study in Children and Adolescents With Severe Plaque Psoriasis
Phase 3Completed 15 Feb 2019 SKIPPAIN - Speed of Onset of SecuKinumab-Induced Relief From Pain in Patients With AxIal SpoNdyloarthritis
Phase 3Completed 1 Jul 2019 Study of Efficacy and Safety of Secukinumab in Patients With Non-radiographic Axial Spondyloarthritis
Phase 3Completed 13 Sep 2019 Efficacy and Safety of 2 Secukinumab Regimens in 90kg or More Weight Group With Moderate/Severe Chronic Plaque Psoriasis
Phase 3Completed 19 Sep 2019 Study to Assess the Long-term Safety, Tolerability, Efficacy of Secukinumab in Pediatric Patients of Age 6 to <18 Years, With Moderate to Severe Plaque Psoriasis
Phase 3Completed 19 Nov 2019 Study of Efficacy and Safety of Secukinumab 2 mL Auto-injector (300 mg) in Subjects With Moderate to Severe Plaque Psoriasis
Phase 3Completed 11 Dec 2019 Study of Efficacy and Safety of Secukinumab in Psoriatic Arthritis and Axial Spondyloarthritis Patients With Active Enthesitis Including One Achilles Tendon Site
Phase 3Completed 30 Dec 2019 Efficacy of Secukinumab Compared to Adalimumab in Patients With Psoriatic Arthritis
Phase 3Completed 7 Oct 2020 Secukinumab Safety and Efficacy in Juvenile Psoriatic Arthritis (JPsA) and Enthesitis-related Arthritis (ERA)
Phase 3Completed 10 Nov 2020 Study of Power Doppler Ultrasound (PDUS) to Measure Response of Secukinumab Treatment in Patients With Active Psoriatic Arthritis (PsA)
Phase 3Terminated 29 Jun 2021 A Study of Secukinumab Treatment in Patients With Plaque Psoriasis and Coexisting Non-alcoholic Fatty Liver Disease (NAFLD)
Phase 3Completed 23 Sep 2021 Study of Efficacy and Safety of Two Secukinumab Dose Regimens in Subjects With Moderate to Severe Hidradenitis Suppurativa (HS)
Phase 3Completed 1 Oct 2021 This Was a Study of Efficacy and Safety of Two Secukinumab Dose Regimens in Subjects With Moderate to Severe Hidradenitis Suppurativa (HS).
Phase 3Completed 12 Nov 2021 Effect of Secukinumab on Radiographic Progression in Ankylosing Spondylitis as Compared to GP2017 (Adalimumab Biosimilar)
Phase 3Completed 17 Feb 2022 Study to Demonstrate the Efficacy, Safety and Tolerability of an Intravenous Regimen of Secukinumab Compared to Placebo in Subjects With Active axSpA
Phase 3Completed 17 May 2022 Study to Demonstrate the Efficacy, Safety and Tolerability of Intravenous Secukinumab up to 52 Weeks in Subjects With Active Psoriatic Arthritis
Phase 3Completed 2 Jun 2022 Study of Efficacy and Safety of Secukinumab in Chinese Subjects With Active PsA Compared to Placebo.
Phase 3Terminated 16 May 2023 A Study of the Efficacy and Safety of Secukinumab 300 mg in Patients With Thyroid Eye Disease (TED)
Phase 3Completed 26 May 2023 Extension Study to Assess Effects of Non-interrupted Versus Interrupted and Long Term Treatment of Two Dose Regimes of Secukinumab in Subjects With Hidradenitis Suppurativa
Phase 3Terminated 23 Aug 2023 Open-label Extension Study of Efficacy, Safety and Tolerability of Secukinumab in Patients With Active Lupus Nephritis
Phase 3Terminated 13 Sep 2023 Study of Safety, Efficacy and Tolerability of Secukinumab Versus Placebo, in Combination With SoC Therapy, in Patients With Active Lupus Nephritis
Phase 3Completed 3 Apr 2024 Efficacy and Safety Study of Secukinumab in Chinese Participants With Non-radiographic Axial Spondyloarthritis
Phase 3Terminated 17 Oct 2024 Study of Efficacy and Safety of Secukinumab in Participants With Moderate-severe Rotator Cuff Tendinopathy
Phase 3Terminated 17 Oct 2024 Study of Efficacy and Safety of Secukinumab in Participants With Moderate-severe Rotator Cuff Tendinopathy
Phase 3Completed 22 Oct 2024 Efficacy of Secukinumab Compared to Ustekinumab in Adults With Active Psoriatic Arthritis and Failure of TNFα-Inhibitor Treatment
Phase 3Completed 7 Nov 2024 An Extension Study of Subcutaneous Secukinumab in Patients With Juvenile Psoriatic Arthritis (JPsA) and Enthesitis Related Arthritis (ERA)
Phase 3Completed 18 Dec 2024 Study of Efficacy and Safety of AIN457/Secukinumab in Patients With Rotator Cuff Tendinopathy
Phase 3Completed 11 Apr 2025 Phase III Study of Efficacy and Safety of Secukinumab Versus Placebo, in Combination With Glucocorticoid Taper Regimen, in Patients With Giant Cell Arteritis (GCA)
Phase 3Completed 10 Sep 2025 Phase III Study of Efficacy and Safety of Secukinumab Versus Placebo, in Combination With Glucocorticoid Taper Regimen, in Patients With Polymyalgia Rheumatica (PMR)
Phase 3Completed 24 Feb 2026 Efficacy and Safety of Secukinumab in Patients With New Onset of Giant Cell Arteritis Who Are in Clinical Remission
Phase 3Withdrawn 20 Mar 2028 Study to Demonstrate the Efficacy and Safety of Secukinumab up to 224 Weeks in Subjects With Active Peripheral Spondyloarthritis (pSpA).
Phase 2Terminated 19 Aug 2010 An Open Label Safety and Tolerability Study of AIN457 in Patients With Moderate to Severe Crohn's Disease
Phase 2Completed Nov 2012 Safety and Tolerability of AIN457 in Adults (18-65 Years) With Psoriatic Arthritis
Phase 2Completed Dec 2012 Safety and Tolerability of AIN457 in Adults (18-65 Years) With Moderate to Severe Ankylosing Spondylitis
Phase 2Terminated 29 Jan 2013 A 3-arm Proof of Concept Study of AIN457, ACZ885 or Corticosteroids in Patients With Polymyalgia Rheumatica
Phase 2Completed 2 Aug 2019 Study of Efficacy, Safety and Tolerability of AIN457 in Patients With Active Overuse Tendinopathy
Phase 2Completed 8 Jun 2021 A Placebo-controlled Phase 2 Trial to Investigate the Safety and Efficacy of Secukinumab in Giant Cell Arteritis
Phase 2Completed 16 Nov 2021 PoC Study to Evaluate the Efficacy and Safety of Secukinumab 300 mg in Patients With Lichen Planus
Phase 1Completed 12 Mar 2025 Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Intravenous Secukinumab in Patients With GCA or PMR
Phase 4Ended not given Treatment of non-type 2 CRSwNP with anti-IL-17 antibody (secukinumab)
Phase 3Authorised not given A prospective, randomized, controlled, open label, assessor-blinded, parallel-group Phase III clinical trial to evaluate the impact of tapering systemic immunosuppressive therapy in a treat-to-target approach on maintaining minimal disease activity in adult subjects with psoriatic arthritis
Phase 4Authorised not given Proactive therapeutic drug monitoring versus routine care with the novel biologics in psoriasis: a pragmatic, multicentric, randomised, controlled study (HELIOS)
Phase 2Ended not given PIMOC - Personalized targeted therapies in inflammatory complex multi organ disease
Phase 4Authorised not given Toward personalized medicine to guide drug withdrawal in children with juvenile idiopathic arthritis in clinical remission: a randomized clinical trial comparing early versus late drug withdrawal combining imaging and multi-Omics.
Phase 2Authorised not given STARS - Prospective, bayesian, randomized, controlled, open-label, parallel-group, phase II interventional study evaluating efficacy and safety of secukinumab versus standard of care in active severe Takayasu patients
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow Secukinumab

Following is part of Solo: you see every change to Secukinumab the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in